To date, there remains just one drug approved for stroke intervention, tissue plasminogen activator (tPA), but the use of tPA is limited due to its narrow therapeutic time window of 6 to 8 hours from the onset of ischemic stroke. This evidence concerns the gene PLAT and Stroke.